Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes

Journal of Immunotherapy

Volumn 27, Issue 4, 2004, Pages 273-281

  Perricone, Michael A ^a   Smith, Karen A ^a   Claussen, Kirsten A ^a   Plog, Malinda S ^a   Hempel, Donna M ^a   Roberts, Bruce L ^a   St George, Judith A ^a   Kaplan, Johanne M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

B 16 tumor; Cancer vaccine; Cellular immune response; Melanoma associated antigen; Recombinant adenovirus vector

Indexed keywords

ADENOVIRUS VECTOR; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN; MELANOMA VACCINE; TYROSINASE RELATED PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; IMMUNOREACTIVITY; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VACCINE PRODUCTION;

EID: 3042589731     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200407000-00003     Document Type: Article

References (36)

1. Coulie PG, Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol. 2003;15:131-137.
2. Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther. 2001;1:277-290.
3. Ghadersohi A, Chitta K, Greco WR, et al. Tumor antigens and markers for breast and ovarian cancers. Front Biosci. 2002;7:E48-E57.
4. Gitlitz BJ, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol. 2001;19:141-147.
5. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp 100 for cancer therapy. J Immunol. 1996;156:700-710.
6. Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol. 1999;163:699-707.
7. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a "self' antigen" induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA. 1999;96:2982-2987.
8. Tuting T, Gambotto A, DeLeo A, et al. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. 1999;6:73-80.
9. Zhou WZ, Kaneda Y, Huang S, et al. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther, 1999;6: 1768-1773.
10. Bellone M, Cantarella D, Castiglioni P, et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol. 2000;165:2651-2656.
11. Bronte V, Apolloni E, Ronca R, et al. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000;60:253-258.
12. Perricone MA, Claussen KA, Smith KA, et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther. 2000;1:275-284.
13. Xiang R, Lode HN, Chao TH, et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA. 2000;97:5492-5497.
14. Tanaka M, Kaneda Y, Fujii S, et al. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther. 2002;5:291-299.
15. Kim CJ, Cormier J, Roden M, et al. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol. 1998;5: 64-76.
16. Pass HA, Schwarz SL, Wunderlich JR, et al. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am. 1998;4:316-323.
17. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst. 2000;92: 1336-1344.
18. Lewis JJ, Janetzki S, Schaed S, et al. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer. 2000;87:391-398.
19. Nielsen MB, Monsurro V, Migueles SA, et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol. 2000;165:2287-2296.
20. Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother. 2000;23:275-281.
21. Juillard V, Villefroy P, Godfrin D, et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol. 1995;25:3467-3473.
22. Warnier G, Duffour MT, Uyttenhove C, et al. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996;67:303-310.
23. Parish CR, Liew FY. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med. 1972;135:298-311.
24. H1-regulated immune responses to Plasmodium chabaudi chabaudi infection. Infect Immun. 1994;62:2490-2498.
25. Taylor-Robinson AW, Phillips RS. Reconstitution of B-cell-depleted mice with B cells restores Th2-type immune responses during Plasmodium chabaudi chabaudi infection. Infect Immun. 1996;64:366-370.
26. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
27. Kitamura D, Roes J, Kuhn R, et al. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991;350:423-426.
28. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980; 283:139-146.
29. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188:277-286.
30. Hempel DM, Smith KA, Claussen KA, et al. Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR. J Immunol Methods. 2002;259:129-138.
31. Moulin V, Andris F, Thielemans K, et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med. 2000;192:475-482.
32. Linton PJ, Bautista B, Biederman E, et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med. 2003;197:875-883.
33. Macaulay AE, DeKruyffRH, Umetsu DT. Antigen-primed T cells from B cell-deficient JHD mice fail to provide B cell help. J Immunol. 1998;160: 1694-1700.
34. Bystry RS, Aluvihare V, Welch KA, et al. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol. 2001;2:1126-1132.
35. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
36. ReffME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83: 435-445.